Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 22, 2021 - Issue 1
Submit an article Journal homepage
1,896
Views
0
CrossRef citations to date
0
Altmetric
Editorial

What are the key considerations when prescribing pharmacotherapy for sickle cell anemia?

Emily Riehm MeierSickle Cell Research, Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7837-9239View further author information
ORCID Icon
Pages 5-8 | Received 25 Jun 2020, Accepted 01 Sep 2020, Published online: 21 Sep 2020

References

  • Meier ER, Rampersad A. Pediatric sickle cell disease: past successes and future challenges. Pediatric Res. 2017;81(1–2):249–258.
  • Quinn CT, Rogers ZR, McCavit TL, et al. Improved survival of children and adolescents with sickle cell disease. Blood. 2010 Apr 29;115(17):3447–3452.
  • Lanzkron S, Carroll CP, Haywood C Jr. Mortality rates and age at death from sickle cell disease: U.S., 1979-2005. Public Health Rep (Washington, DC: 1974). 2013 Mar-Apr;128(2):110–116.
  • Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med. 1995 May 18;332(20):1317–1322.
  • National Heart Lung and Blood Institute (NHLBI). Evidence-based management of sickle cell disease: expert panel report, 2014. 2014. http://www.nhlbi.nih.gov/health-pro/guidelines/sickle-cell-disease-guidelines.
  • Niihara Y, Zerez CR, Akiyama DS, et al. Oral L-glutamine therapy for sickle cell anemia: I. Subjective clinical improvement and favorable change in red cell NAD redox potential. Am J Hematol. 1998 Jun;58(2):117–121.
  • Niihara Y, Miller ST, Kanter J, et al. A phase 3 trial of l-glutamine in sickle cell disease. N Engl J Med. 2018 Jul 19;379(3):226–235.
  • Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017 Feb 2;376(5):429–439.
  • Han J, Saraf SL, Gordeuk VR. Systematic review of crizanlizumab: a new parenteral option to reduce vaso-occlusive pain crises in patients with sickle cell disease. Pharmacotherapy. 2020 Jun;40(6):535–543.
  • Han J, Saraf SL, Gordeuk VR. Systematic review of voxelotor: a first-in-class sickle hemoglobin polymerization inhibitor for management of sickle cell disease. Pharmacotherapy. 2020 Jun;40(6):525–534.
  • Vichinsky E, Hoppe CC, Ataga KI, et al. A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med. 2019 Aug 8;381(6):509–519.
  • Gluckman E, Cappelli B, Bernaudin F, et al. Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood. 2017 Mar 16;129(11):1548–1556.
  • King A, Shenoy S. Evidence-based focused review of the status of hematopoietic stem cell transplantation as treatment of sickle cell disease and thalassemia. Blood. 2014 May 15;123(20):3089–3094. quiz 210.
  • Ribeil JA, Hacein-Bey-Abina S, Payen E, et al. Gene Therapy in a Patient with Sickle Cell Disease. N Engl J Med. 2017 Mar 02;376(9):848–855.
  • Meier ER, Fasano RM, Levett PR. A systematic review of the literature for severity predictors in children with sickle cell anemia. Blood Cells Mol Dis. 2017 Jun;65:86–94.
  • Meier ER. Treatment options for sickle cell disease. Pediatr Clin North Am. 2018;65(3):427–443.
  • Rai P, Ataga K. Drug therapies for the management of sickle cell disease F1000. Res. 2020;11(9):F1000Faculty Rev–592.
  • Ballas S. The evolving pharmacotherapeutic landscape for the treatment of sickle cell disease. Mediterr J Hematol Infect Dis. 2020;12(1):e2020010.
  • Lanzkron S, Haywood C Jr., Hassell KL, et al. Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease Adult Provider Network. J Natl Med Assoc. 2008 Aug;100(8):968–973.
  • Brandow AM, Jirovec DL, Panepinto JA. Hydroxyurea in children with sickle cell disease: practice patterns and barriers to utilization. Am J Hematol. 2010 Aug;85(8):611–613.
  • Oyeku SO, Driscoll MC, Cohen HW, et al. Parental and other factors associated with hydroxyurea use for pediatric sickle cell disease. Pediatr Blood Cancer. 2013 Apr;60(4):653–658.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.